95% CI, 0.75 to 1.23) or the rate of death (HR, 0.94
What Experts Are Watching Next The medical community is keeping a close eye on several key variables as next-generation obesity medications move through development pipelines: Long-Term Cardiovascular Outcomes: Major trials are underway to confirm that retatrutides multi-agonist profile translates into a lower risk of stroke, heart attack, and cardiovascular death
This concept of tailoring therapy to patients needs and preferences plays an important role in treatment choices, particularly for older adults with T2D who, in general, have higher rates of premature death, functional disability, and coexisting illnesses, and are at greater risk for several common geriatric syndromes, such as polypharmacy, cognitive impairment, urinary incontinence, and injurious falls
Are there side effects that might slow my semaglutide weight loss progress
Many product information leaflets note that upper-arm injections may require assistance from another person